cyrilzakka/clinical-trials huggingface dataset:
Exercise and Manual Therapy for Shoulder Subacromial Impingement Syndrome

The purposes of this study are to:

1. determine if a rehabilitation program that consists of exercise and manual therapy reduces pain and improves quality of life in patients with shoulder subacromial impingement syndrome;
2. determine which patients are likely to respond to this rehabilitation program and which patients are not likely to respond to this rehabilitation program

The hypotheses are:

1. the rehabilitation treatment program will result in significant changes in pain and quality of life
2. there will be items from the history and examination that will identify those patients who respond favorably and those who do not respond favorably to rehabilitation at 6 weeks, 3, 6 and 12 months.

Subacromial impingement syndrome (SAIS) is the most frequent cause of shoulder pain. A variety of non-surgical treatments have been advocated to correct the impairments associated with SAIS. Clinical trials support the use of therapeutic exercise and joint mobilizations to improve pain and functional disability associated with SAIS. However, not all patients in these trials had a favorable outcome. Moreover, the effect sizes in these trials were small to moderate. Thus the purposes of this study are to 1. determine the effect of a multi-modal rehabilitation program consisting of strengthening, stretching, manual therapy to the shoulder and spine, patient education, posture, and functional re-training; and 2. identify those patients who are and who are not likely to respond to rehabilitation at the start of care.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of shoulder impingement syndrome as evidence by all 5 criteria:

  1. Reproduction of symptoms with impingement test: either Hawkins-Kennedy or Neer Test
  2. Pain during active shoulder elevation at or above 60 degrees
  3. Weakness of rotator cuff or pain during the Empty Can test or during resisted shoulder external rotation
  4. Shoulder disability: greater than or equal to 20/100 (0 = no disability)
  5. Able to understand written and spoken English

Exclusion Criteria:

* Severe pain; pain is \> or equal to 7/10 on NPRS (0 = no pain)
* Shoulder surgery on affected shoulder
* Traumatic shoulder dislocation within the past 3 months
* Previous rehabilitation for this episode of shoulder pain
* Reproduction of shoulder pain with active or passive cervical motion
* Systemic inflammatory joint disease
* Global loss of passive shoulder ROM, indicative of adhesive capsulitis
Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS

This project will investigate the ability of a novel MRI contrast agent to identify and quantitate ongoing monocyte/macrophage (M/MΦ)-mediated inflammation in the brains of HIV-infected individuals.

HIV-associated neurocognitive disorders (HAND) continue to be prevalent despite effective combination antiretroviral therapy (cART) and have a significant impact on morbidity and quality of life. Monocytes/macrophages (M/MΦ) are believed to play a critical role in the pathogenesis of HAND. Neuroimaging HIV research has not focused on assessing M/MΦ-mediated inflammation in the brain. Currently, no neuroimaging modality exists that can define the extent of active inflammation due to M/MΦ in HAND either as a clinical diagnostic tool or to assist in defining objective improvement in clinical trials addressing HAND. Ferumoxytol is an ultra-small iron oxide MRI contrast agent avidly taken up by circulating M/MΦ. The investigators hypothesize that ferumoxytol-based imaging can identify ongoing inflammation due to perivascular M/MΦ which is believed to represent a key pathologic correlate of HAND.

Eligibility Criteria:
Inclusion Criteria:

* Age 40-65 years
* Plasma HIV RNA \< 48 copies/ml (HIV+ subjects only)
* On stable cART \>= 1 year (HIV+ subjects only)
* Global neuropsychological (NP) score \<-0.5 in at least one cognitive domain known to be affected by HIV (neurocognitively impaired subjects only)
* Documentation of negative HIV infection by an FDA approved test (HIV- subjects only)

Exclusion Criteria:

* Active substance use
* History of myocardial infarct or stroke
* Diabetes
* Chronic hepatitis C virus (HCV) infection
* Uncontrolled major affective disorder, active psychosis, central nervous system disease that affects the brain structure, or other uncontrolled chronic medical condition that in the opinion of the investigator may impact NP testing or the study outcome
* Psychoactive or other medications which may impact NP testing
* Factors that preclude MRI
* Known hypersensitivity to ferumoxytol
* History of laboratory measurements consistent with an iron overload syndrome
* Medical conditions that require frequent blood transfusions
* Taking oral iron supplements
* Elevated iron levels
* Any condition, which in the opinion of the investigator, would compromise the subject's ability to participate
* Multiple drug allergies that may pose a greater risk of anaphylaxis associated with ferumoxytol
* Pregnant, unwillingness to practice birth control, or breastfeeding
* Unable to give informed consent
Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With Hematuria

Our goal is to develop a noninvasive, fast and simple assay to detect BCa on the GeneXpert system and metablomic genes.

The Xpert BCa monitor is a novel mRNA-based urine test that measures five mRNA targets (ABL1, ANXA10, UPK1B, CRH, and IGF2) in urine sample by real time RT-PCR. Previous studies had investigated the feasibility and diagnostic performance characteristics of Xpert monitor for surveillance of NMIBC patients (12, 13). It demonstrated a high SN and NPV in relation to urine cytology.

On the other hand, metabolic dysfunction has been implicated in a wide variety of human diseases including BC (14). Growth and division of tumor cells are associated with an increase in the activity of a variety of metabolic pathways. Significant alterations in the carnitine-acylcarnitine metabolic pathways were detected in urine speci¬mens from BC patients compared to those of healthy controls (15). The expression of six genes involved in the carnitine-acylcarni¬tine metabolic pathway (CPT1A, CPT1B, CPT1C, CPT2, SLC25A20, and CRAT) was assessed by Won and colleagues. CRAT and SLC25A20 were found to be significantly down regulated in BC patients (16).

In this context, we aimed in the current study at prospective assessment of diagnostic performance characteristics of Xpert Bladder Cancer Monitor (Xpert Monitor) test and urinary metabolomics (urinary metabolites of tissue mRNA genes expression CRAT and SLC 25A20) for bladder cancer detection in patients with hematuria.

Eligibility Criteria:
Inclusion Criteria:

* Patients with gross or persistent microscopic hematuria with irritative bladder symptoms

Exclusion Criteria:

* patients on anticoagulants
* patients with history of radiotherapy
Longitudinal Study in Clinically Isolated Syndrome (CIS) Patients Treated With Interferon Beta

The aim of this study is to evaluate the role of cognitive disorders and quality of life in patients with CIS, considered as high risk to develop an MS, treated with interferon Beta. This prospective observational study will include 120 patients, all treated and evaluated annually with neurological extensive examination, ophthalmologic screening (OCT, OF, VEP, VF), auto questionnaire about fatigue (musicol, ELIF), quality of life (SEP-59), and conventional MRI.


Eligibility Criteria:
Inclusion Criteria:

* Patients older than 18 years,
* Patients with CIS and temporo spatial dissemination for less than one year
* Patient without prior immunomodulatory treatment
* Patient informed of CIS diagnosis and MS according to McDonald criteria,
* Patients with EDSS inferior or egal to 5,5
* Patients usually french-reader and with MMS \>24
* Patients informed of study protocol
* Patients agree to sign informed consent
* Patients with affiliation number from social French département.

Exclusion Criteria:

* Secondary progressive MS
* Patient with acute relapse
* Patient already treated with IFN
* corticosteroids less than 15 days
* Patient with severe dépressive disorders
* Patient already included in clinical study
* Patient \< 18 years
* Patient with known contra indications for beta interféron
* Every reason with can provoke an interruption of the study, regarding a patient empechment
* Contre indications for MRI or other tests required in the study
* pregnancy or lactation
* patient Under juridic protection
Evaluation of Fingertip Precision Pinch Force in Fibromyalgia Patients

This study aims to evaluate the force used by fibromyalgia patients during a task compared to healthy volunteers and to evaluate its relationship with fatigue seen in these patients.

Fatigue is a common symptom in fibromyalgia patients and it is known that these patients have decreased muscle strength compared to healthy volunteers. The aim of this study was to evaluate whether the minimum force to be applied during carrying is different in fibromyalgia patients compared to healthy volunteers.

Eligibility Criteria:
Inclusion Criteria:

-Female patients diagnosed with fibromyalgia between the ages of 18-70

Exclusion Criteria:

* Those whose treatment has been changed in the last month
* Those with shoulder, elbow, wrist and hand diseases that may cause pain in the dominant upper extremity
* Those with carpal or cubital tunnel syndrome
* Those with a history of orthopedic surgery in the dominant extremity
* Those with uncontrolled metabolic disease
* Those with B12 deficiency
This Trial Aims to Assess the Effects of Three Different Taste-based Dietary Recommendations for Reducing Free Sugar Intakes on Free Sugar Consumption in UK High Free Sugar Consumers

This randomised controlled trial aims to assess the effects of three different taste-based dietary recommendations for reducing free sugar intakes on free sugar consumption in UK high free sugar consumers.

This 12-week, 3-arm randomised controlled trial aims to assess the effects of three different taste-based food and beverage substitution instructions for reducing free sugar intakes on free sugar consumption in high free sugar consumers. A total of 180 adult community members residing in Bournemouth and the surrounding areas will be recruited. All participants will be asked to reduce their intakes of free sugar and replace sweet, high-free sugar foods and beverages with either: 1) sweet tasting foods and beverages that have no or low amounts of free sugars; 2) non-sweet tasting foods and beverages that have no or low amounts of free sugars and are high in other tasty flavours; and 3) non-sweet tasting foods and beverages that have no or low amounts of free sugars and are also low in other flavours. The primary outcome of interest is the changes in free sugar intakes from baseline to endpoint. Secondary outcomes include a range of dietary and biopsychosocial outcomes, sweet taste perceptions and sweet food and beverage intakes, as well as compliance with and evaluation of the dietary recommendation received.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18 and over
2. Consuming more than 10% total daily energy from free sugars (-3% for testing error)
3. Residing in the South of England, and able to attend Bournemouth University for testing (Talbot Campus, BH12 5BB)
4. Able to provide consent and complete all study-related measures

Exclusion Criteria:

1. Being a smoker or having smoked in the last 3 months
2. Being pregnant or breastfeeding
3. Being underweight (BMI \< 18.5 kg/m²)
4. Dieting or following a specific diet program (e.g., Weight Watchers, Keto diet, or Intermittent Fasting)
5. Following a specific diet or nutritional advice as a result of pre-existing medical condition (e.g., Crohn's disease, diabetes)
6. Having a pre-existing medical condition or taking medication that could affect taste and/or smell abilities (e.g., certain blood pressure and heart medications)
7. Allergies to foods and drinks used in the study
SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma

This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of SBRT for perivascular hepatocellular carcinoma, compared with RFA.

The primary endpoint is 1-year local recurrence rate and disease-free survival. We planned to recruit 170 patients who diagnosed as perivascular hepatocellular carcinoma. The patients will be randomized into SBRT group and RFA group as 1:1 ratio.

Eligibility Criteria:
Inclusion Criteria:

1. Primary hepatocellular carcinoma or recurrent hepatocellular carcinoma after curative treatment.
2. Unifocal tumor ≤5cm
3. Closed to great vessels (diameter ≥3mm)
4. ECOG score 0-1
5. Child-Pugh grade A or B7
6. Sufficient liver and kidney function

Exclusion Criteria:

1. Vascular invasion
2. Extra-hepatic metastasis
3. Received TACE before
4. Inflammation of local skin
5. Dysfunction of liver, kidney or bone marrow.
6. Concomitant other malignant tumor or HIV infection
Effect of Intravenous Dexamethasone With Pudendal Nerve Block on Postoperative Pain in Pediatric Hypospadias Repair

This study aims to determine if intravenous Dexamethasone combined with a pudendal nerve block is able to prolong postoperative analgesia in children undergoing hypospadias repair.

It was a prospective study, randomized, double blind study, conducted at the Tunis Children's Hospital (January 2017-December 2018). After agreement with parents and the local ethics committee, the investigators included children aged 1 to 18 years, ASA 1-2, proposed for a hypospadias repair. Patients were randomized to: Group D receiving 0. 15mg/kg of Dexamethasone IV after induction and group P receiving the same volume of saline. The pudendal block was performed by neurostimulation after induction with Sevoflurane and 3 gamma/kg Fentanyl IV. The success of the block was tested at 10 and 15 minutes, it was declared successful when the systolic blood pressure and heart rate did not increase by more than 20% compared to the baseline values at the time of the incision. No analgesics were administered at the end of the surgery. The pain was assessed by the CHEOPS score the first 24 hours. The X2 test was used for qualitative variables and the student test for quantitative variables with P\<0. 05 as the significance threshold. The number of patients required for the study was calculated (alpha=5% beta=90%) and was 62.

Eligibility Criteria:
Inclusion Criteria:

* ASA physical status classification 1 or 2
* Procedure: hypospadias repair
* Eligible for a pudendal nerve block

Exclusion Criteria:

* parents or patient refusal
* nerve block failure
* Peroperative complication.
Acupuncture for Sexual Dysfunction

Female Sexual Dysfunction (FSD) affects up to 43% of women in the United States and Hypoactive Sexual Desire Disorder (HSDD) is the most common form. There is no standardized treatment for this condition. We know that alternative therapies such as acupuncture have been beneficial to women suffering from urinary incontinence, chronic lower back pain, and migraines. We hypothesize that the quality of life for premenopausal women with hypoactive sexual desire disorder (HSDD) will improve with initiation of acupuncture therapy for a duration of 5-weeks. Validated questionnaires are administered at the time of enrollment and 1 week after the final acupuncture session as the method of analyzing our primary outcome.

Each woman will receive experimental therapy with acupuncture twice a week for five weeks and complete a packet of validated questionnaires/surveys at the 1st visit in person and at week 6 by mail.

The acupuncture sessions include:

* An Initial Evaluation in which the certified acupuncturist will take a
* History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood
* Physical Exam: inspection of tongue and palpation of pulse
* 25 minutes of resting quietly with acupuncture needles in place
* Needle usage: from8 to 20 needles are typically used, with an average of 14 per session
* Needles are typically placed on the scalp, lower abdomen, elbows and knees

Subsequent Sessions (9 more) with the certified acupuncturist

* 25 minute each, twice weekly, for 5 weeks = total 10 sessions
* Needle usage = 8-20, average 14 per session
* Typically placed on the scalp, lower abdomen, elbows and knees

The questionnaires/surveys include questions about:

* Sexual desire, arousal, lubrication, orgasm, satisfaction and pain
* General physical health
* General emotional and psychological health
* Social relationships

Eligibility Criteria:
Inclusion Criteria:

* Women aged 18-55 years
* Sexually Active
* Premenopausal
* Documented diagnosis of HSDD as primary cause of FSD (defined as a non adjusted score of ≤ 6 in the desire domain of the FSFI questionnaire)

Exclusion Criteria:

* Postmenopausal, defined as absence of menstruation in the prior 12 months
* Pain or dyspareunia as the primary cause of FSD (defined as a non adjusted score of ≤ 6 in the pain domain of the FSFI)
* History of hysterectomy and/or oophorectomy
* History of chemotherapy, or pelvic irradiation
* Use of hormonal contraception or oral hormone replacement therapy
* Active skin infection or disease
* Blood dyscrasia
* Allergy to acupuncture needles
RRT for PTSD Symptoms in Survivors of Sexual Violence

Study to provide evidence of efficacy for Rapid Resolution Therapy in symptoms of PTSD, Anxiety, and Depression in survivors of sexual violence.

The investigators will recruit 24 participants to complete pre-test measures, participate in a 3 hour therapy session of Rapid Resolution Therapy (RRT), and then re-test one week post treatment and 6 months follow up.

If participants do not report a "good result" following the 3 hour session, the investigators will offer a 1.5 hour follow up session Participants will receive free therapy for their participation, but will not be paid.

Participants will be men and women over the age of 18 who do not have a diagnosis of psychosis and are not actively suicidal and have experienced a single rape at least 3 months before enrolling in the study.

Sessions will be audio recorded and transcribed for construct validity (of RRT). Identifying in formation will be removed by the study coordinator before transcripts are coded for validity.

This study proposes to use the same methods as Rothbaum et al (2005) published in Journal of Traumatic Stress that compares Prolonged Exposure to Eye Movement and Desensitization and Reprocessing (EMDR) for PTSD Rape Victims. The investigators will compare our results to theirs. Both of their treatments were 8 sessions, and this study's treatment is one. They also include data for a control group.

Eligibility Criteria:
Inclusion Criteria:

* 18-70 years old
* self report experiencing a rape any time before 3 months prior to treatment
* on PCL-C (Positive for PTSD)

  * score 3-5 on at least one item 1-5
  * score 3-5 on at least 3 items 6-12
  * score 3-5 on at least 2 items 13-17

Exclusion Criteria:

* history of schizophrenia or psychosis current
* suicidal risk
* in an ongoing threatening situation (i.e. domestic violence)
* participants who are pregnant or become pregnant during the study (if someone becomes pregnant during the study, we will complete treatment if she desires, but will not include data)
Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

PRIMARY OBJECTIVE:

I. To assess the maximum tolerated dose (MTD) of paclitaxel via intraperitoneal route in subjects with gastric or gastroesophageal cancer and positive cytology or carcinomatosis.

SECONDARY OBJECTIVES:

I. Safety and tolerability of escalating doses of intraperitoneal paclitaxel in subjects with gastric or gastroesophageal cancer and positive cytology or carcinomatosis.

II. To make a preliminary assessment of the anti-tumor activity of paclitaxel in subjects with stage IV gastric or gastroesophageal cancer and positive cytology or carcinomatosis.

OUTLINE: This is a dose-escalation study.

Patients receive paclitaxel intraperitoneally (IP) over 1 hour once weekly during weeks 1-3 and 5-7 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for 5 years.

Eligibility Criteria:
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
* Cytologic or histologic proof of adenocarcinoma of the stomach or gastroesophageal junction
* Leukocytes \>= 3,000/uL
* Absolute neutrophil count \>= 1,500/uL
* Platelets \>= 60,000/Ul
* Serum creatinine =\< 1.5 mg/dL
* Distant metastatic disease of peritoneum:

  * Positive peritoneal cytology
  * Carcinomatosis on diagnostic laparoscopy or laparotomy
  * Completion of preoperative systemic chemotherapy

Exclusion Criteria:

* Infections such as pneumonia or wound infections that would preclude protocol therapy
* Women with a positive urine or serum pregnancy test are excluded from this study; women of childbearing potential (defined as those who are not postmenopausal defined as no menses in greater than or equal to 12 months, have not had a hysterectomy or bilateral salpingo-ophorectomy, do not have ovarian failure, or have not had a surgical sterilization procedure) must agree to refrain from breast-feeding and practice adequate contraception as specified in the informed consent. Adequate contraception consists of oral contraceptive, implantable contraceptives, injectable contraceptives, a double barrier method, or abstinence. Men with reproductive potential must agree to an appropriate method of birth control, including abstinence or double barrier method (diaphragm plus condom)
* Subjects with unstable angina or New York Heart Association Grade II or greater congestive heart failure
* Subjects deemed unable to comply with study and/or follow-up procedures
* Subjects with a known hypersensitivity to protocol systemic chemotherapy that was life-threatening, required hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability or incapacity
* Previous surgery that would preclude safe diagnostic laparoscopy with port placement